Home » Stocks » Edesa Biotech

Edesa Biotech, Inc. (EDSA)

Stock Price: $6.67 USD -1.04 (-13.49%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $6.55 -0.12 (-1.80%) Oct 20, 7:50 PM

Stock Price Chart

Key Info

Market Cap 64.09M
Revenue (ttm) 738,671
Net Income (ttm) -5.27M
Shares Out 9.61M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $6.67
Previous Close $7.71
Change ($) -1.04
Change (%) -13.49%
Day's Open 7.62
Day's Range 6.60 - 7.92
Day's Volume 479,789
52-Week Range 1.58 - 19.10

More Stats

Market Cap 64.09M
Enterprise Value 58.63M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 9.61M
Float 3.09M
EPS (basic) -0.59
EPS (diluted) -0.73
FCF / Share -0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 97,802
Short Ratio 0.31
Short % of Float 3.17%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 86.77
PB Ratio 13.49
Revenue 738,671
Operating Income -5.36M
Net Income -5.27M
Free Cash Flow -4.58M
Net Cash 5.46M
Net Cash / Share 0.57
Gross Margin 47.14%
Operating Margin -725.81%
Profit Margin -713.30%
FCF Margin -620.31%
ROA n/a
ROE n/a
ROIC -1,730.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $6.67
Target: 16.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth--82.05%67.62%103.88%-31.78%90.69%-58.97%-
Gross Profit--0.310.14-0.08-0.39-0.06-0.25-0.31
Operating Income-1.62-5.22-4.91-4.34-5.72-3.85-6.55-4.83
Net Income-1.87-5.03-5.03-2.84-8.44-14.50-5.53-3.60
Shares Outstanding3.
Earnings Per Share-0.47-20.64-23.94-15.12-46.62-118.02-54.60-37.80
Operating Cash Flow-1.29-4.70-4.51-4.41-4.27-2.80-3.95-2.62
Capital Expenditures-0.01-0.30-0.40-0.27-0.28-0.01-0.08-0.31
Free Cash Flow-1.30-5.00-4.91-4.69-4.54-2.81-4.03-2.93
Cash & Equivalents3.376.5711.418.97-7.861.004.15
Net Cash / Debt3.376.5711.418.97-7.861.004.15
Book Value3.217.4012.318.01--2.200.853.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Edesa Biotech, Inc.
Country Canada
Employees 10
CEO Pardeep Nijhawan

Stock Information

Ticker Symbol EDSA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EDSA


Edesa Biotech, a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.